Xencor, Inc.
Edit Page
Report
Scan day: 12 February 2014 UTC
19
Virus safety - good
Description: Technology for MHC epitope removal, glycosylation to optimize pharmacokinetics, masking immune recognition sites and engineering monoclonal antibodies. Includes discovery programs, partnering opportunities in Monrovia, California. ImmunoPDA Technology Product Sheet Caltech spin-off developing proteomic technologies to accelerate drug discovery.
Xencor | Engineering Antibodies for Breakthrough Therapeutics Leerink Swann Global Healthcare Conference (Bassil Dahiyat, Ph.D., presenting; New York, NY Webcast: http://leerink.metameetings.com/confbook/healthcare14/directlink?ticker=XNCR)
Size: 240 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Xencor | Engineering Antibodies for Breakthrough Therapeutics |
| Keywords: | |
| Description: | Xencor is developing superior monoclonal antibody therapeutics optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. |
| IP-address: | 205.134.241.48 |
WHOIS Info
| NS | Name Server: NS0.DNSMADEEASY.COM Name Server: NS1.DNSMADEEASY.COM Name Server: NS2.DNSMADEEASY.COM Name Server: NS3.DNSMADEEASY.COM Name Server: NS4.DNSMADEEASY.COM |
| WHOIS | Status: clientTransferProhibited |
| Date | Creation Date: 28-aug-1997 Expiration Date: 27-aug-2016 |